INFINITY PHARMACEUTICALS INC's ticker is INFI and the CUSIP is 45665G303. A total of 143 filers reported holding INFINITY PHARMACEUTICALS INC in Q4 2014. The put-call ratio across all filers is 2.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $8,000 | -75.0% | 6,154 | +1.5% | 0.00% | – |
| Q1 2016 | $32,000 | -8.6% | 6,061 | +34.2% | 0.00% | – |
| Q4 2015 | $35,000 | -31.4% | 4,515 | -25.0% | 0.00% | – |
| Q3 2015 | $51,000 | +168.4% | 6,022 | +252.4% | 0.00% | – |
| Q2 2015 | $19,000 | 0.0% | 1,709 | +28.5% | 0.00% | – |
| Q1 2015 | $19,000 | -13.6% | 1,330 | +0.2% | 0.00% | – |
| Q4 2014 | $22,000 | 0.0% | 1,327 | -17.6% | 0.00% | – |
| Q3 2014 | $22,000 | +15.8% | 1,610 | +5.3% | 0.00% | – |
| Q2 2014 | $19,000 | +18.8% | 1,529 | +10.7% | 0.00% | – |
| Q1 2014 | $16,000 | -15.8% | 1,381 | +2.8% | 0.00% | – |
| Q4 2013 | $19,000 | -76.8% | 1,343 | -71.3% | 0.00% | -100.0% |
| Q3 2013 | $82,000 | +105.0% | 4,680 | +91.6% | 0.00% | – |
| Q2 2013 | $40,000 | – | 2,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,354,963 | $38,132,000 | 1.80% |
| Orbimed Advisors | 4,520,800 | $73,201,000 | 1.55% |
| QVT Financial LP | 1,326,610 | $21,480,000 | 1.44% |
| BB BIOTECH AG | 1,089,828 | $17,646,000 | 1.27% |
| Meditor Group Ltd | 250,000 | $4,048,000 | 0.55% |
| Perimeter Capital Partners, LLC | 159,915 | $2,589,000 | 0.50% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 156,808 | $2,539,000 | 0.43% |
| Broadfin Capital, LLC | 117,172 | $1,897,000 | 0.37% |
| OXFORD ASSET MANAGEMENT LLP | 811,331 | $13,184,000 | 0.36% |
| Baker Brothers Advisors | 1,016,433 | $16,458,000 | 0.33% |